Idera Pharma - Comparative Multiple Analysis

Idera Pharma (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of Idera Pharma

WikiWealth compares Idera Pharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Idera Pharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Idera Pharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Idera Pharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Idera Pharma's Analysis

How does this work? The Comparative Investment Analysis determines the value of Idera Pharma by comparing Idera Pharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Idera Pharma.

See the Idera Pharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Idera Pharma.

Also, see the Idera Pharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Idera Pharma's valuation conclusion for a quick summary.